This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Y-mAbs Therapeutics Croissance future
Future contrôle des critères 1/6
Les bénéfices de Y-mAbs Therapeutics devraient diminuer de 4.4% par an tandis que son chiffre d'affaires annuel devrait croître de 18.1% par an. Le BPA devrait croître de de 1.4% par an. Le rendement des capitaux propres devrait être -74.9% dans 3 ans.
Informations clés
-4.4%
Taux de croissance des bénéfices
1.38%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 25.4% |
| Taux de croissance des recettes | 18.1% |
| Rendement futur des capitaux propres | -74.93% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 05 Sep 2025 |
Mises à jour récentes de la croissance future
Article d’analyse • May 16
Earnings Update: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
A week ago, Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) came out with a strong set of first-quarter numbers that could...Article d’analyse • Mar 07
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported And Analysts Have Been Cutting Their Estimates
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shareholders are probably feeling a little disappointed, since its shares...Recent updates
Seeking Alpha • Aug 06
Y-mAbs Therapeutics: The Next Deal Showcases The Value And Challenges Of Biotech M&A
Summary Y-mAbs Therapeutics announced that it would be acquired at a >100% premium relative to recent trading. The deal showcases how little optimism there is in the biotech market at this time, even though recent investors are seeing substantial gains. This article lays out what SERB is going to get, and what I feel this transaction means for near-term biotech M&A. Read the full article on Seeking Alpha
Mise à jour du récit • Aug 06
Pipeline Developments And Radiopharmaceutical Advances Will Extend Global Reach
Despite improved profitability—with net profit margin rising to 12.26% and a lower future P/E of 47.56x—analysts have cut Y-mAbs Therapeutics’ consensus price target from $14.70 to $11.68, suggesting tempered growth expectations. What's in the News SERB S.A.S. agreed to acquire Y-mAbs Therapeutics for approximately $398.67 million ($8.6 per share); deal approved by Y-mAbs board and expected to close by December 31, 2025, subject to antitrust approval.Article d’analyse • May 16
Earnings Update: Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
A week ago, Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) came out with a strong set of first-quarter numbers that could...Article d’analyse • Apr 29
Insufficient Growth At Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Hampers Share Price
Y-mAbs Therapeutics, Inc.'s ( NASDAQ:YMAB ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a strong...
Nouveau récit • Mar 31
DANYELZA And Radiopharmaceuticals Realignment Will Energize Global Opportunities
Strategic realignment into DANYELZA and Radiopharmaceuticals could enhance revenue growth and operational efficiency through focused business units.Article d’analyse • Mar 07
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported And Analysts Have Been Cutting Their Estimates
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shareholders are probably feeling a little disappointed, since its shares...Seeking Alpha • Jan 24
Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials
Summary YMAB's naxitamab sales declined from Q3 2023 to Q3 2024, but the company has a strong cash runway, supporting operations until 2027. Upcoming data readouts for GD2-SADA in Q2 2025 are critical for assessing the viability of their radiotherapy platform, most notably concerns related to toxicity. Despite risks, YMAB's current market cap of $270 million may be a bargain if upcoming data provides a clear clinical direction. I reiterate a "Buy" sentiment, with reservations about naxitamab sales growth and the uncertain future of GD2-SADA. Read the full article on Seeking AlphaArticle d’analyse • Jan 10
Benign Growth For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Underpins Stock's 26% Plummet
To the annoyance of some shareholders, Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shares are down a considerable 26% in...Article d’analyse • Dec 10
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Article d’analyse • Nov 19
The Market Doesn't Like What It Sees From Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues Yet As Shares Tumble 26%
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shareholders that were waiting for something to happen have been dealt a blow...Seeking Alpha • Oct 21
Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers
Summary Y-mAbs Therapeutics' naxitamab is approved for R/R High-Risk Neuroblastoma, with ongoing trials to expand its use, but the market size is limited. Financially, YMAB has a market cap of $644 million and a cash runway of 4-5 quarters, raising concerns about its ability to fund future R&D. The company is focusing on the SADA platform, but the lack of efficacy data makes it a speculative investment at this stage. Despite promising prospects, YMAB's low cash reserves and small market potential for naxitamab warrant a cautious investment approach. Read the full article on Seeking AlphaArticle d’analyse • Sep 12
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shares have had a really impressive month, gaining 33% after a shaky period...Seeking Alpha • Aug 12
Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)
Summary YMAB maintains a market valuation around $500 million, potential for substantial appreciation. Pipeline updates include expanding the naxitamab market and progressing SADA radioimmunotherapeutic. Financially, YMAB has $77.8 million in cash, growing product revenues, and a cash runway of 8-9 quarters. Read the full article on Seeking AlphaArticle d’analyse • Jul 15
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Article d’analyse • Jun 02
Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%
The Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • May 09
Y-mAbs: There's A Ceiling Here Somewhere
Summary Y-mAbs Therapeutics has experienced a significant recovery in value but lacks upcoming catalysts for near-term growth. Their approved therapy, naxitamab, has shown promising results in treating pediatric cancers. Y-mAbs' GD2-SADA pipeline project has potential but carries high risk, and the company's financials are stable for now. Read the full article on Seeking AlphaArticle d’analyse • Mar 14
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Y-mAbs...Article d’analyse • Feb 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shares have continued their recent momentum with a 66% gain in the last month...Seeking Alpha • Jan 14
Y-mAbs Therapeutics: A Monoclonal Antibody Play
Summary Y-mAbs Therapeutics' shares have rebounded massively since March 2023 due to the company's restructuring, extending its cash runway until 2027. The company's main commercial asset is Danyelza, a monoclonal antibody for the treatment of neuroblastoma, which has shown promising sales. Y-mAbs is also evaluating Danyelza for other indications and has a novel cancer treatment program called SADA, but these are still in early stages. Chase the rally or time to take some profits? A full investment analysis follows in the paragraphs below. Read the full article on Seeking AlphaArticle d’analyse • Nov 13
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2027 | 109 | -59 | -67 | -60 | 7 |
| 12/31/2026 | 95 | -49 | -54 | -20 | 9 |
| 12/31/2025 | 83 | -30 | -39 | -26 | 10 |
| 6/30/2025 | 85 | -22 | -18 | -18 | N/A |
| 3/31/2025 | 89 | -28 | -19 | -19 | N/A |
| 12/31/2024 | 88 | -30 | -16 | -16 | N/A |
| 9/30/2024 | 85 | -24 | -22 | -22 | N/A |
| 6/30/2024 | 87 | -25 | -13 | -13 | N/A |
| 3/31/2024 | 84 | -22 | -18 | -18 | N/A |
| 12/31/2023 | 85 | -21 | -27 | -27 | N/A |
| 9/30/2023 | 93 | -19 | -28 | -28 | N/A |
| 6/30/2023 | 85 | -39 | -46 | -46 | N/A |
| 3/31/2023 | 75 | -74 | -64 | -64 | N/A |
| 12/31/2022 | 65 | -96 | -76 | -76 | N/A |
| 9/30/2022 | 43 | -134 | -102 | -101 | N/A |
| 6/30/2022 | 40 | -135 | -100 | -100 | N/A |
| 3/31/2022 | 40 | -117 | -96 | -96 | N/A |
| 12/31/2021 | 35 | -55 | -104 | -103 | N/A |
| 9/30/2021 | 46 | -38 | -87 | -86 | N/A |
| 6/30/2021 | 37 | -42 | -93 | -92 | N/A |
| 3/31/2021 | 26 | -60 | -102 | -101 | N/A |
| 12/31/2020 | 21 | -119 | -91 | -91 | N/A |
| 9/30/2020 | N/A | -123 | -99 | -98 | N/A |
| 6/30/2020 | N/A | -114 | -97 | -95 | N/A |
| 3/31/2020 | N/A | -91 | -84 | -82 | N/A |
| 12/31/2019 | N/A | -81 | -75 | -73 | N/A |
| 9/30/2019 | N/A | -72 | -63 | -62 | N/A |
| 6/30/2019 | N/A | -59 | -51 | -50 | N/A |
| 3/31/2019 | N/A | -52 | N/A | -48 | N/A |
| 12/31/2018 | N/A | -43 | N/A | -41 | N/A |
| 9/30/2018 | N/A | -38 | N/A | -34 | N/A |
| 6/30/2018 | N/A | -31 | N/A | -27 | N/A |
| 3/31/2018 | N/A | -24 | N/A | -19 | N/A |
| 12/31/2017 | N/A | -19 | N/A | -16 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: YMAB devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: YMAB devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: YMAB devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de YMAB ( 18.1% par an) devrait croître plus rapidement que le marché US ( 11.9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de YMAB ( 18.1% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: YMAB devrait être non rentable dans 3 ans.
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2025/09/15 00:36 |
| Cours de l'action en fin de journée | 2025/09/15 00:00 |
| Les revenus | 2025/06/30 |
| Revenus annuels | 2024/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Y-mAbs Therapeutics, Inc. est couverte par 8 analystes. 10 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Peter Lawson | Barclays |
| Yun Zhong | Brean Capital Historical (Janney Montgomery) |
| Thomas Shrader | BTIG |